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Abstract
Background: The molecular pathways involved in the interstitial lung diseases (ILDs) are poorly understood.
Systems biology approaches, with global expression data sets, were used to identify perturbed gene networks, to
gain some understanding of the underlying mechanisms, and to develop specific hypotheses relevant to these
chronic lung diseases.
Methods: Lung tissue samples from patients with different types of ILD were obtained from the Lung Tissue
Research Consortium and total cell RNA was isolated. Global mRNA and microRNA were profiled by hybridization
and amplification-based methods. Differentially expressed genes were compiled and used to identify critical
signaling pathways and potential biomarkers. Modules of genes were identified that formed a regulatory network,
and studies were performed on cultured cells in vitro for comparison with the in vivo results.
Results: By profiling mRNA and microRNA (miRNA) expression levels, we found subsets of differentially
expressed genes that distinguished patients with ILDs from controls and that correlated with different disease
stages and subtypes of ILDs. Network analysis, based on pathway databases, revealed several disease-associated
gene modules, involving genes from the TGF-b, Wnt, focal adhesion, and smooth muscle actin pathways that
are implicated in advancing fibrosis, a critical pathological process in ILDs. A more comprehensive approach was
also adapted to construct a putative global gene regulatory network based on the perturbation of key
regulatory elements, transcription factors and microRNAs. Our data underscores the importance of TGF-b
signaling and the persistence of smooth muscle actin-containing fibroblasts in these diseases. We present
evidence that, downstream of TGF-b signaling, microRNAs of the miR-23a cluster and the transcription factor
Zeb1 could have roles in mediating an epithelial to mesenchymal transition (EMT) and the resultant persistence
of mesenchymal cells in these diseases.
Conclusions: We present a comprehensive overview of the molecular networks perturbed in ILDs, discuss several
potential key molecular regulatory circuits, and identify microRNA species that may play central roles in facilitating
the progression of ILDs. These findings advance our understanding of these diseases at the molecular level,
provide new molecular signatures in defining the specific characteristics of the diseases, suggest new hypotheses,
and reveal new potential targets for therapeutic intervention.
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The interstitial lung diseases (ILDs), a broad category of
restrictive lung disorders, exhibit cellular infiltration and
distortion of the interstitium and alveolar gas units [1].
Current descriptions of ILDs at the tissue or cell levels
include broadly defined processes such as aberrant
wound repair, scarring, apoptosis, or fibrosis, whereas at
the molecular level, these diseases are associated with
dysregulation of a complex set of cytokines, growth fac-
tors, and signaling molecules [1-4]. In particular, the
TGF-b [4-6] and the Wnt signaling pathways [4,7,8] are
thought to have key roles in the disease. Recently,
through global gene expression profiling, several studies
have revealed more fundamental processes involved
ILDs, including extracellular matrix remodeling [9],
alterations in the cytoskeleton [10], and the possibility
that a process similar to the developmental epithelial to
mesenchymal cell transition gives rise to the fibroblasts
that are prominent in idiopathic pulmonary fibrosis and
the other ILDs [6,10]. In addition to understanding the
disease better, gene expression profiling results have
also improved the pathological classification of the ILDs
[11,12].
MicroRNAs (miRNAs), small, 21-25 nucleotide long
non-coding RNAs, can regulate global gene networks by
interacting with specific messenger RNAs (mRNAs) to
repress translation or hasten mRNA degradation [13,14].
Based on a computational prediction model, microRNA
molecules may also be hubs in the regulation of gene
networks, as a single miRNA can affect the function of
numerous mRNAs [15]. In fact, as many as one-third of
all mRNAs, including a large number of transcription
factors may be regulated by miRNAs [16,17]. Specific
miRNAs have already been implicated in lung biology
[18-20]; for example, deleting miRNAs of the miR-
17~miR-92 cluster prevents normal lung development
[21], while over-expression of this cluster leads to
epithelial cell proliferation in the lung [18].
The systems biology approach is to view the biological
system as a whole in order to study the effects of disease
and global interactions with the environment, which
facilitates understanding of biological processes and dis-
ease [22,23]. The five key components for systems biol-
ogy are the global measurements of biomolecules, the
integration of biological information, the identification
of molecular responses to perturbations, the building of
testable models, and the refinement of models through
testing of these hypotheses. Once the models accurately
represent the specific biological responses, they can be
used to understand disease progression, identify new
disease intervention points, and predict the molecular
responses to perturbations [24].
To better understand the complex pathology asso-
ciated with ILDs and identify molecular networks
involved in the disease, we took a systems biology
approach to acquire and integrate changes of mRNA
and miRNA levels between biopsy samples from patients
with ILD and from normal lung tissue. First, we found
distinct molecular signatures that distinguish patients
from controls, and that may differentiate patients with
one subtype of ILD (IPF, idiopathic pulmonary fibrosis)
from another type (NSIP, non-specific interstitial pneu-
monitis). Next, we identified known signaling pathways
that were characterized with differentially expressed
modules of genes in greater detail than in previous stu-
dies. We then integrated differentially expressed mRNAs
with selected, differentially expressed miRNAs and tran-
scription factors (TFs) and produced an initial global
view of the molecular changes that are present in the
ILDs. This analysis also revealed several potential dis-
ease-associated regulatory circuits, including events
downstream of TGF-b signaling that may play a role in
disease persistence. We present data showing that miR-
NAs in the miR-23a cluster, downstream of TGF-b and
Zeb-1, may have a role as positive regulators of the
epithelial to mesenchymal transition, which has been
proposed to play an important role in ILD pathogenesis.
While there are aspects of the ILDs that our models do
not describe, by using a systems approach we have iden-
tified several potentially important regulatory networks,
leading to new candidates for biomarkers for disease
stratification and progression, and putative therapeutic
targets for these debilitating diseases.
Methods
Ethics Statement
The project was conducted in compliance with U.S. 45
CFR 46 ("Common Rule”) as administered by the Office
of Human Research Protections within the United States
Department of Health and Human Services. The Com-
mon Rule is derived from the basic ethical principles
espoused in the Belmont Report (http://ohsr.od.nih.gov/
guidelines/belmont.html). This project utilized de-identi-
fied tissue samples acquired through the Lung Tissue
Research Consortium (LTRC #07-99-0006; ltrcpublic.
com), Lifeline of Ohio and the Cooperative Human Tis-
sue Network (CHTN). The use of these samples was
approved at the Ohio State University under IRB proto-
col 2007H0002.
Description of study population
Lung tissue samples from thirty patients with IPF or
related disorders were obtained from the Lung Tissue
Research Consortium (http://www.ltrcpublic.com).
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nosed with usual interstitial pneumonia/idiopathic pul-
monary fibrosis (UIP/IPF), nine samples came from
patients with non-specific interstitial pneumonia (NSIP),
four from patients with uncharacterized fibrosis, and the
remaining samples came from patients with other ILD
variants (Table 1). Biopsies from uninvolved lung tissue
from lung cancer patients (5 samples) and from one
lung transplant patient were used as controls for com-
parison with the IPF samples.
RNA isolation and microarray profiling
Total RNA was isolated from individual human lung
samples by homogenization in TRIzol
® Reagent per the
manufacturer’s protocol (Invitrogen, Carlsbad, CA)
using Soft Tissue Omni Homogenizer Tips (Omni Inter-
national; Marietta, GA). The quality and quantity of the
RNA samples were evaluated for concentration and pur-
ity using a NanoDrop ND-1000 Spectrophotometer
(NanoDrop; Wilmington, DE), and for integrity by gel
electrophoresis using the FlashGel
® RNA cassette sys-
tem (Lonza; Rockland, ME). The mRNA expression pro-
files in the samples were obtained with Affymetrix
GeneChip
® H u m a nG e n o m eU 1 3 3P l u s2 . 0A r r a y( c o n -
taining 39,000 genes) as described in the Affymetrix
GeneChip
® protocol. MicroRNAs were profiled by using
microarrays from Agilent Technologies (G4470B, Santa
Clara, CA) as well as by RT-PCR. The levels of selected
mRNA and miRNA observed on microarray studies
were validated by using a SYBR-based quantitative RT-
PCR method [25]. More detailed protocols are in Addi-
tional file 1.
Microarray data analysis and network construction
Affymetrix array data was summarized, normalized, and
transformed in log2-scale by the GCRMA method [26]. For
the Agilent miRNA array, a consolidated intensity value
for each probe was obtained, quantile normalized [27]
Table 1 Demographic and clinical information of 29 samples used for mRNA/miRNA profiling
Sample ID Group FVC % Gender Age Race Cigarette smoking Clinical diagnosis RNA profiling
4 1 < 50% Male 37 Caucasian Unknown UIP/IPF mRNA/miRNA
6 1 < 50% Female 45 African-American Never UIP/IPF mRNA/miRNA
7 1 < 50% Female 26 Caucasian Never FU mRNA/miRNA
9 1 < 50% Male 64 Caucasian Previous UIP/IPF mRNA
10 1 < 50% Female 58 Caucasian Never UIP/IPF mRNA/miRNA
11 2 50~80% Male 58 Caucasian Unknown UIP/IPF mRNA/miRNA
12 2 50~80% Female 66 Caucasian Never NSIP mRNA
13 2 50~80% Male 57 Caucasian Previous NSIP mRNA/miRNA
14 2 50~80% Male 60 Caucasian Unknown UIP/IPF mRNA/miRNA
16 2 50~80% Male 61 Caucasian Previous UIP/IPF mRNA/miRNA
17 2 50~80% Female 69 Caucasian Never HP mRNA/miRNA
19 2 50~80% Male 68 Caucasian Previous UIP/IPF mRNA/miRNA
20 2 50~80% Male 80 Caucasian Previous NSIP mRNA
21 3 > 80% Male 65 Caucasian Previous NSIP mRNA/miRNA
22 3 > 80% Male 52 Hispanic Never RB-ILD mRNA/miRNA
23 3 > 80% Male 39 Caucasian Previous RB-ILD mRNA/miRNA
24 3 > 80% Male 61 Caucasian Previous COP mRNA/miRNA
25 3 > 80% Female 68 Caucasian Never UIP/IPF mRNA
26 3 > 80% Male 53 Caucasian Never COP mRNA/miRNA
27 3 > 80% Female 50 African-American Previous NSIP mRNA/miRNA
28 3 > 80% Female 66 Caucasian Previous HP mRNA/miRNA
29 3 > 80% Male 64 Caucasian Previous UIP/IPF mRNA/miRNA
30 3 > 80% Male 56 Caucasian Previous UIP/IPF mRNA/miRNA
43 Normal - Female 71 Caucasian Unknown Uninvolved carcinoma tissue mRNA/miRNA
44 Normal - Female 81 Caucasian Unknown Uninvolved carcinoma tissue mRNA/miRNA
46 Normal - Male 50 Caucasian Unknown Uninvolved carcinoma tissue mRNA/miRNA
48 Normal - Male 73 Caucasian Unknown Uninvolved carcinoma tissue mRNA/miRNA
50 Normal - Female 73 Caucasian Unknown Uninvolved carcinoma tissue mRNA/miRNA
51 Normal - Male 29 Unknown Previous Lung transplant patient mRNA/miRNA
Abbreviation : FVC (forced vital capacity), UIP/IPF (usual interstitial pneumonitis/idiopathic pulmonary fibrosis), NSIP (non-specific interstitial pneumonitis), HP
(hypersensitive pneumonitis), COP (cryptogenic organizing pneumonia), RB-ILD (respiratory bronchiolitis-interstitial lung disease).
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or absent by applying a Gaussian mixture model. We used
only these present mRNA probe sets for subsequent statis-
tical analysis, but for miRNA data, all probes were used.
A detailed description of data analysis and network con-
struction is given in Additional file 1. All microarray data-
sets have been uploaded to the GEO database. mRNA
results are in GSE21369 while miRNA results are in
GSE21394. A ‘super series’ designation of GSE21411 was
assigned to both of these datasets.
MDCK cell culture
MDCK cells (ATCC, Manassas, VA) were maintained in
DMEM containing 10% fetal bovine serum, 2 mM
L-glutamine, 0.1 mM non-essential amino acids, 100 U
of penicillin, and 100 μg streptomycin (Invitrogen). For
isolation of epithelial and mesenchymal subclones, single
cells were sorted into 96-well plates using a FACSAria II
cell sorter (BD Biosciences, San Jose, CA). Clones were
picked based on morphology. Clones with clear epithe-
lial or mesenchymal morphology were expanded. Canine
Zeb1 cDNA was amplified by PCR and cloned into
pcDNA3.1 directional TOPO expression vector (Invitro-
gen). Cells were transfected using Lipofectamine 2000
(Invitrogen) according to the manufacturer’sp r o t o c o l .
Zeb1-transfected cells were selected with G418 at 1 mg/
mL for approximately 3 weeks.
Western blots
T75 flasks of MDCK cells were rinsed once in PBS and
then lysed in NP40 lysis buffer (Invitrogen) containing
protease inhibitor cocktail (Pierce, Rockford, IL) for
30 minutes on ice. Lysates were cleared by centrifuga-
tion at 13,000 rpm at 4°C for 20 minutes. Lysates were
run on a 4-12% NuPAGE gradient gel (Invitrogen) and
transferred to Immobilon-FL membrane (Millipore, Bill-
erica, MA). The membrane was blocked for 1 hour in
5% nonfat dry milk diluted in PBS, then incubated over-
night at 4°C in primary antibodies diluted in 5% bovine
serum albumin in PBS. Primary antibodies were used as
follows: rabbit anti-Nedd4L antibody (1:1000; Cell Sig-
naling Technology, Danvers, MA) and mouse anti-Ago2
(1:1000; Abcam, Cambridge, MA). After rinsing 5× in
PBS + 0.1% Tween-20 (PBT), the membrane was incu-
bated for 1 hour in donkey anti-mouse 680LT and goat
anti-rabbit 800CW secondary antibodies (LI-COR bios-
ciences, Lincoln, NE) in PBS +0.2% Tween-20 and
0.01% SDS. After 5 more rinses in PBT, the membrane
was scanned on a LI-COR Odyssey scanner (LI-COR).
Quantitative PCR
RNA was isolated from MDCK cells using the Qiagen
miRNeasy kit according to the manufacturer’sp r o t o c o l
(Qiagen, Valencia, CA). For each RNA sample, 150 ng
of RNA was reverse transcribed using the miScript kit
(Qiagen). cDNAs were diluted 10-fold then used in
SYBR-based qPCR reactions. Primers for canine miR-
23a, 24, 27a and for canine Zeb1 and Gusb mRNAs
were ordered from IDT (Coralville, IA).
Results
Sample characteristics
Thirty post-surgical tissue specimens obtained from the
Lung Tissue Research Consortium (http://www.ltrcpublic.
com) from patients diagnosed with different types of ILDs,
and more specific diagnoses, as described in Table 1, were
analyzed. To validate the pathology of these samples, his-
tological examinations were conducted on a limited num-
ber of randomly picked samples. The results displayed a
classical histopathological profile for ILD tissues: replace-
ment of regular alveolar structures with extensive scar tis-
sue and extracellular matrix (Additional file 2).
Ten specimens were obtained in each of three Forced
Vital Capacity (FVC) groups, less than 50% (FVC 1),
50 to 80% (FVC 2), and greater than 80% (FVC 3). Due
to RNA quality or unsuccessful microarray hybridization
in some of the samples, we obtained five mRNA profil-
ing results from the FVC 1 group, eight profiles from
the FVC group 2, and ten profiles from the FVC group
3. For controls, one specimen of lung tissue from a nor-
mal donor and 11 specimens of uninvolved lung tissue
from patients with lung cancer were processed, ostensi-
bly free of interstitial lung disease. Six of these 12 sam-
ples gave acceptable global gene expression profiles. We
also obtained miRNA expression information for the 6
control and 19 of the 23 ILD samples for which we
have mRNA expression information (Table 1).
Differentially expressed genes and microRNAs
We focused our initial efforts on identifying genes that
were significantly altered in ILD tissues relative to con-
trols by a factor of 1.5-fold or greater, with a positive
false discovery rate (pFDR) of < 0.1 (see Additional file
1). Using these criteria, we identified 1423 differentially
expressed genes (DEGs), where 795 genes were over-
expressed and 628 genes were under-expressed in ILD
samples relative to the controls. The changes of selected
DEGs were verified with qPCR (Additional file 3). Using
hierarchical clustering analysis, the DEGs clustered the
samples into two very distinct groups: one group with
ILD patient samples and the other with normal controls
(Figure 1). In the ILD cluster, the DEGs also separated
the samples into three different subgroups (Figure 1),
which generally correlated with the disease types and
lung function.
Similarly, we also identified 125 differentially expressed
miRNAs (DEmiRNAs) between the ILD patient samples
and controls. Among the 125 DEmiRNAs, 82 showed
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trols. We observed a slight, but interesting, gender bias
in the expression levels of DEmiRNAs (lower levels in
females), especially for the normal samples (data not
shown). Using the same hierarchical clustering
approach, the samples can also be grouped into two
major classes based only on the DEmiRNAs (Figure 2).
While most of the normal samples were separated from
the ILDs, one cryptogenic organizing pneumonia (COP)
sample was grouped with the controls and one normal
sample was grouped with the ILDs. The clustering
results from DEmiRNAs did not exhibit a clear separa-
tion of the samples either by type or disease severity
(FVC groups) as the DEGs did.
ILDs can be subclassified by using pairs of DEGs and
DEmiRNAs
Several pairs of genes and miRNAs that could discrimi-
nate samples between ILDs and controls, and among
different FVC groups, were identified by ranking pairs of
genes and miRNAs that had reciprocal expression
profiles between the groups of samples (see Additional
file 4) [28]. The most robust pairs of genes and miR-
NAs, collagen, type III, alpha 1 (COL3A1) and Rho gua-
nine nucleotide exchange factor 7 (ARHGEF7), and
miR-99b and miR-21*, could perfectly discriminate the
ILD samples from controls in this set (see Additional
file 5).
The same approach was applied to segregate IPF sam-
ples from NSIP. NSIP showed distinct clinical outcomes
and pathology when compared to IPF [29], but the two
disease types displayed extreme similarity in their overall
gene and miRNA expression profiles. A few genes,
however, showed significant differences between the two
disease types. For example, the ratio between hydroxys-
teroid (17-beta) dehydrogenase 6 homolog (HSD17B6)
and a hypothetical protein, C2orf40 expression levels,
separate NSIP and IPF clearly (see Additional file 5).
Identifying pathways associated with ILD
The lists of DEGs and DEmiRNAs provide an inventory
of molecules affected by the diseases. These lists are
valuable in the identification of potential biomarkers for
the diseases, but to gain a better understanding of the
functional implications of these mRNAs and miRNAs,
we performed an enrichment analysis to identify KEGG
pathways [30] associated with DEGs and to acquire
functional correlations from the Gene Ontology (GO)
project [31].
Figure 1 Hierarchical clustering with 1423 differentially
expressed genes between ILD patient and normal control lung
samples. Each row represents the expression profile of a gene
across 29 samples and each column represents a sample. The
sample IDs and clinical information (FVC group and diagnosis) are
listed below the heatmap. Red or green colors indicate either
higher or lower expression levels of the gene. Based on the
dendrogram, the samples can be further separated into four
subgroups indicated by red, green, blue and black bars below the
heatmap which correlate with ILD other than UIP/IPF, less severe
UIP/IPF (FVC 2 and 3), more severe UIP/IPF (FVC 1), and normal
control, respectively.
Figure 2 Hierarchical clustering result of 125 differentially
expressed miRNAs. The sample IDs and clinical information (FVC
group and diagnosis) are listed below the heatmap. Red or green
colors indicate either higher or lower expression levels of the
miRNA. Samples are well separated into control and ILD patient
groups except two.
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strongly associated with pathways including ECM-
receptor interaction, cell-cell communication, focal
adhesion and B-cell signaling, based on the results of
pathway enrichment analyses. Innate immune responses
(Toll-like receptor signaling pathways), adipocytokine
signaling pathways and metabolic processes are asso-
ciated with down-regulated DEGs in ILD samples (see
Table 2 for a list of some key pathways). The full list of
enriched pathways is given in Additional file 1. The
Wnt and insulin signaling pathways are associated with
a similar number of up- and down-regulated genes
which probably reflect the heterogeneity of the tissue
samples and dynamic nature of the diseases. Detailed
molecular descriptions of the key pathways involved in
the ILDs are provided as Additional file 6.
To explore the possible functional implications of the
observed changes in miRNA expression profiles between
ILDs and controls, we assembled a comprehensive list
of all the potential DEmiRNA target genes identified by
TargetScan (version 5.1) [32]. These 7547 presumptive
mRNA targets were searched against the master list of
differentially expressed mRNAs and 805 were found in
common. Pathways enriched by these putative
DEmiRNA-targeted DEGs were similar to the pathways
associated with the entire 1423 DEGs described earlier.
The high degree of consistency in the enriched pathways
clearly suggests coherent interactions between the miR-
NAs and mRNAs and the involvement of these signifi-
cantly enriched common pathways in the disease (see
Table 2 and Additional file 1). Keeping in mind that
mRNA levels may not be affected by those miRNAs that
regulate translation efficiency, and that the levels of
miRNA need not always result in mRNA level changes,
this observation on the consistency of affected pathways
is highly significant.
Using the DEmiRNA-targeted DEGs, we identified
6555 putative DEmiRNA-DEG interaction pairs. Since
miRNAs are thought to be largely negative regulators of
their targeted genes, the list of DEmiRNA-DEG interac-
tions was reduced to 1530 pairs with 107 distinct
DEmiRNAs and 440 DEGs (FDR<0.1, see Additional
file 1), by selecting those with inverse correlation on
their expression patterns. As previously reported [33],
results from our pathway enrichment analyses using
DEGs and DEmiRNA targets also indicated a strong
involvement of the Wnt pathway in ILDs. The Wnt
pathway has been implicated in the control of tissue
homeostasis in metazoan organisms, and dysregulation
of the pathway, leads to a variety of abnormalities in
many tissues, including developmental defects, cancers,
and neurological disorders [34]. To elucidate the com-
plex interactions between mRNAs and miRNAs in the
Wnt signaling network in ILDs, we examined these
presumptive DEmiRNA-DEG interactions in some detail
(Figure 3). Several differentially expressed genes between
ILD samples and controls in Wnt pathway are heavily
targeted by DEmiRNAs; for example, F-box and WD
repeat domain containing 11 (FBXW11)a n df r i z z l e d
homolog 5 (FZD5) (Figure 3, green circles) were down-
regulated and likely were “targeted” by up-regulated
DEmiRNAs (Figure 3, red triangles) such as miR-199-3p
and miR-200b, while the nuclear factor of activated T-
cells 5 (NFAT5) is up-regulated and targeted by down-
regulated DEmiRNAs including miR-30 family members
and others (Figure 3, green triangles). The cell surface
receptor VanGogh-like 1 (VANGL1) is also up-regulated
and it is another predicted target of down-regulated
miR-30 and miR-181 family members. As discussed
l a t e r ,w es u s p e c tt h a tt h en e te f f e c to ft h i sm i R N At a r -
geting is to keep signaling through the Wnt pathway
persistent and chronic, leading to effective disease pro-
gression and persistence.
The transcription factor and miRNA mediated molecular
network presents a systems view of the ILD family of
diseases
Besides using manually curated KEGG pathways to
assess functional implications of the DEGs and DEmiR-
NAs, we also took a more global approach by focusing
specifically on differentially expressed transcription fac-
tors (DETFs) and miRNAs, of which any alteration may
lead to profound changes in the normal global molecu-
lar network. Among the DEGs, there were 106 tran-
scription factors or putative transcription factors
identified [35], where 65 of them showed higher levels
in the ILD samples. For example, myocardin (MYOCD),
a smooth muscle fibroblast-associated transcription fac-
tor [36], was one of the most elevated TFs in the ILD
samples, while the most suppressed TF in the ILD sam-
ples was nuclear receptor subfamily 4, NR4A2,ap u l -
monary epithelial cell differentiation-associated gene
[37]. This finding fits well with ILD pathology: a signifi-
cant increase of myofibroblasts accompanied by a sharp
decrease of lung pulmonary epithelial cells. The changes
of MYOCD and NR4A2 mRNA levels in ILD imply the
possibility of using TF-mediated networks to gain
insight into the state of pathology.
Combining predicted DETF-DEmiRNA and DETF-
DEG transcriptional interactions based on conserved
transcription binding site information and expression
profiles with protein-protein interactions and curated
interactions in the KEGG database, we built a molecular
network centered on twenty-two well-characterized
DETFs (see Additional file 1 for details). There are a
large number of DEmiRNA-DEG (non-DETF) interac-
tion pairs (681 pairs having FDR<0.05 and 1470 pairs
having FDR<0.1, see Additional file 1), and the effects of
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Page 6 of 20Table 2 KEGG pathways enriched by DEGs, all DEmiRNA target genes and all DEmiRNA target DEGs
All DEGs All DEmiRNA predicted targets DEGs that are DEmiRNA predicted
targets
KEGG pathway Up-
regulated
DEGs
Down-
regulated
DEGs
All targets of
down-regulated
DEmiRNAs
All targets of
up-regulated
DEmiRNAs
DEG targets of
down-regulated
DEmiRNAs
DEG targets of
up-regulated
DEmiRNAs
Signal
Transduction
Calcium signaling
pathway
4.0E-01 1.0E + 00 4.6E-04 2.7E-03 4.1E-02 9.5E-01
ErbB signaling pathway 3.4E-01 3.5E-01 9.3E-05 6.4E-08 1.3E-01 4.2E-01
Hedgehog signaling
pathway
4.2E-02 4.7E-01 2.8E-02 6.2E-04 8.1E-03 6.1E-01
Jak-STAT signaling
pathway
6.0E-01 3.9E-01 7.6E-02 7.6E-02 1.0E-01 2.5E-01
MAPK signaling pathway 2.0E-01 9.5E-02 1.7E-08 1.3E-16 1.3E-01 1.6E-01
mTOR signaling pathway 5.3E-01 2.0E-01 1.1E-02 2.6E-07 1.0E + 00 5.3E-02
Notch signaling pathway 7.2E-02 1.6E-01 1.4E-01 5.4E-03 2.9E-01 5.4E-01
Phosphatidylinositol
signaling system
2.5E-01 8.6E-01 8.2E-05 3.9E-06 1.1E-01 3.6E-01
TGF-beta signaling
pathway
3.4E-01 5.5E-01 4.3E-08 1.9E-06 4.8E-01 1.0E + 00
VEGF signaling pathway 2.5E-01 1.2E-01 7.4E-02 2.2E-03 4.3E-01 3.6E-02
Wnt signaling pathway 4.9E-03 7.4E-03 1.4E-05 1.3E-14 7.2E-04 3.3E-03
Signaling
Molecules and
interactions
Cell adhesion molecules
(CAMs)
8.1E-02 9.4E-01 8.4E-01 2.9E-01 7.4E-02 6.5E-01
ECM-receptor interaction 5.7E-07 9.0E-01 2.7E-04 9.3E-06 3.1E-03 1.0E + 00
Behavior Circadian rhythm -
mammal
1.0E + 00 1.1E-01 3.1E-02 1.6E-02 1.0E + 00 1.9E-01
Cell
Communication
Adherens junction 1.2E-01 9.7E-01 1.1E-04 1.1E-09 4.3E-01 1.0E + 00
Focal adhesion 9.6E-09 5.5E-01 1.4E-07 8.8E-17 3.1E-03 8.5E-01
Gap junction 3.7E-01 1.0E + 00 1.1E-02 4.7E-06 2.8E-02 1.0E + 00
Tight junction 4.7E-01 3.9E-01 8.3E-03 3.9E-06 6.3E-01 1.8E-01
Cell Growth
and Death
Apoptosis 8.1E-01 4.4E-02 2.7E-02 6.5E-03 1.0E + 00 4.3E-01
Cell cycle 9.4E-01 3.5E-01 7.3E-03 1.4E-01 6.2E-01 8.9E-01
p53 signaling pathway 6.8E-01 8.6E-02 1.5E-02 4.4E-03 4.0E-01 3.1E-01
Cell Motility Regulation of actin
cytoskeleton
1.9E-01 5.0E-01 2.2E-05 1.4E-12 4.7E-01 4.8E-01
Circulatory
System
Vascular smooth muscle
contraction
5.6E-06 1.0E + 00 3.0E-03 1.0E-03 1.6E-04 1.0E + 00
Development Axon guidance 6.8E-02 6.9E-01 1.2E-08 3.9E-15 6.7E-02 3.6E-01
Dorso-ventral axis
formation
5.8E-01 1.0E + 00 4.0E-04 1.3E-02 1.0E + 00 1.0E + 00
Endocrine
System
Adipocytokine signaling
pathway
3.9E-01 1.5E-04 2.0E-02 2.3E-05 3.9E-01 7.4E-04
GnRH signaling pathway 2.6E-01 4.8E-01 4.8E-03 1.6E-04 3.8E-02 2.4E-01
Insulin signaling pathway 2.2E-03 1.9E-02 2.6E-03 7.0E-11 7.9E-02 2.5E-02
Melanogenesis 6.8E-01 9.9E-01 2.9E-03 1.2E-06 1.7E-01 8.2E-01
PPAR signaling pathway 1.0E + 00 1.9E-01 6.6E-01 8.1E-01 1.0E + 00 2.6E-02
With genes in each module of the network, pathway enrichment analysis was performed using one-sided Fisher exact test. The significance level of p-value is
represented by regular (0.01~0.1), bold (0.0001~0.01) and bold-italic (<0.0001) fonts.
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Page 7 of 20the DEmiRNA-DETF interactions are expected to be key
to regulation of many other genes. Thus, we decided
first to focus on the effects of the DEmiRNA-DETF
interactions. The entire network (excluding DEmiRNA-
DEG interactions) is still large and contains 689 nodes
(562 DEGs, 49 DEmiRNAs and 78 DETFs) with 1391
interactions (Figure 4). Out of the 22 DETFs, 17 have
predicted interactions with DEmiRNAs. The majority of
the DETF-DEmiRNA interactions are centered on
6 TFs, which represent the core of the network. They
are nuclear receptor subfamily 2, group F, member 1
(NR2F1), JUN, nuclear factor of activated T-cells, cyto-
plasmic, calcineurin-dependent 4 (NFATC4), zinc finger
E-box binding homeobox 1 (ZEB1), nuclear transcrip-
tion factor Y, alpha (NFYA) and CCAAT/enhancer bind-
ing protein (C/EBP), delta (CEBPD). Based on the
network topology, this global DEG/DETF/DEmiRNA
interaction network could be grouped into seven large
modules (labeled as 1 to 7 on Figure 4a). We also
attempted to sub-group the networks based on KEGG
pathways but the attempt was not very successful, since
there are too many shared genes among different “path-
ways” (Additional file 7). Though the pathway-based
analysis has some disadvantages relative to a purely
topological approach, it revealed that there are 84 genes
in the network related to signal transduction and 69
genes involved in the immune system. This suggests the
strong involvement of immune response and cell-cell
communication related pathways in processes associated
with ILDs. The GO term and KEGG pathway enrich-
ment analyses revealed that genes in module 1 are
enriched with metabolic-related terms and pathways. In
addition, module 1 also contained all the smooth mus-
cle-actin-related genes from the vascular smooth muscle
contraction pathway. Module 2 contained genes
involved in the immune response, cellular signaling pro-
cess and cell-cell communication. Module 3 contained
genes involved in lipid metabolism, and module 7 con-
tained genes associated with adipocytokine and insulin
signaling processes. The Wnt pathway is associated with
module 6, while the MAPK pathway is associated with
module 4 and 5 (Table 3 and Additional file 1).
Figure 3 Integrated view of Wnt pathway. All (present) genes associated with the Wnt pathway are denoted with by circular nodes and their
fold-change values are represented by node color where red and green indicate higher and lower expression in ILD patient samples compared
to controls, respectively. Bold-faced gene symbols indicate DEGs. Triangular nodes represent DEmiRNAs which have reciprocal expression fold-
change values relative to their presumptive mRNA targets or that are predicted to be regulated by differentially expressed transcription factors
(FDR<0.1, see Additional file 1). The transcription factors used in construction of this regulatory network are shown as squares and their fold-
changes were expressed by node border colors. Gray and black lines indicate protein-protein interactions and signaling information from the
KEGG database, respectively. Red, blue and green lines with arrows represent predicted transcriptional activation, transcriptional repression and
miRNA-mediated repression, respectively. Open circles represent transcription factors that were not used in prediction of regulatory interactions.
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Page 8 of 20Figure 4 A hypothetical network based on differentially expressed transcription factors and DEmiRNAs. Molecular interactions obtained
from protein-protein interactions, KEGG pathway interactions, putative transcriptional regulatory interactions derived from 1423 DEGs, and
predicted DEmiRNA and DETF interactions were combined. (A). The network containing 689 nodes composed of 22 DETFs (open squares), 618
DEGs (filled circles) and 49 DEmiRNAs (filled triangles) and 1391 non-redundant interactions was generated. The network can be grouped into 7
modules (as indicated) based on the connectivity of nodes - the more interacted nodes are grouped together. (B) This figure displays only the
network consisting of the DETF (with known binding sites) and their cognate DEmiRNAs. The transcription factors, which do not have well
characterized binding site information were not used in prediction of interactions, and are shown as open circles.
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Page 9 of 20Table 3 Pathways associated with different network modules
Module
KEGG Pathway 1 2 3 4 5 6 7
Metabolism Amino Acid Metabolism Cysteine and methionine metabolism 7E-02
Glycine, serine and threonine metabolism 5E-02
Valine, leucine and isoleucine degradation 8E-03
Biosynthesis of Secondary Metabolites Terpenoid backbone biosynthesis 8E-03
Carbohydrate Metabolism Butanoate metabolism 7E-02
Inositol phosphate metabolism 1E-02
Propanoate metabolism 7E-02
Pyruvate metabolism 3E-02
Energy Metabolism Reductive carboxylate cycle (CO2 fixation) 3E-02
Glycan Biosynthesis and Metabolism Glycosaminoglycan degradation 2E-03
Glycosphingolipid biosynthesis - ganglio series 7E-02
Heparan sulfate biosynthesis 4E-02
Lipid Metabolism Arachidonic acid metabolism 2E-02
Ether lipid metabolism 8E-02
Fatty acid elongation in mitochondria 2E-02
Fatty acid metabolism 3E-02
Glycerolipid metabolism 2E-03
Glycerophospholipid metabolism 1E-02
Sphingolipid metabolism 2E-02
Steroid biosynthesis 8E-05
Synthesis and degradation of ketone bodies 3E-02
Metabolism of Cofactors and Vitamins Nicotinate and nicotinamide metabolism 5E-04
One carbon pool by folate 7E-02
Metabolism of Other Amino Acids Selenoamino acid metabolism 4E-02
Xenobiotics Biodegradation and Metabolism Benzoate degradation via CoA ligation 6E-02
Caprolactam degradation 8E-03
Genetic Information Processing Folding, Sorting and Degradation RNA degradation 2E-02
Environmental Information Processing Signal Transduction ErbB signaling pathway 2E-02
Hedgehog signaling pathway 4E-05
Jak-STAT signaling pathway 1E-02
MAPK signaling pathway 8E-02 5E-03 2E-03
mTOR signaling pathway 1E-02
Notch signaling pathway 4E-03
Phosphatidylinositol signaling system 4E-02
TGF-beta signaling pathway 4E-02 1E-02
VEGF signaling pathway 6E-02 9E-03
Wnt signaling pathway 1E-02 1E-04
Signaling Molecules and Interaction Cell adhesion molecules (CAMs) 3E-02
Cytokine-cytokine receptor interaction 4E-03 6E-02
ECM-receptor interaction 1E-02
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0Table 3 Pathways associated with different network modules (Continued)
Cellular Processes Cell Communication Adherens junction 3E-02
Focal adhesion 1E-02 5E-04 3E-02
Tight junction 4E-04
Cell Growth and Death Apoptosis 2E-02
Cell cycle 8E-02
p53 signaling pathway 3E-02
Cell Motility Regulation of actin cytoskeleton 9E-04
Circulatory System Vascular smooth muscle contraction 4E-06
Development Axon guidance 7E-02 7E-02
Endocrine System Adipocytokine signaling pathway 3E-02 2E-06
GnRH signaling pathway 9E-02
Insulin signaling pathway 2E-05 1E-02 7E-05
Immune System Antigen processing and presentation 8E-02
B cell receptor signaling pathway 8E-03
Chemokine signaling pathway 2E-09
Complement and coagulation cascades 1E-02
Fc epsilon RI signaling pathway 4E-02
Fc gamma R-mediated phagocytosis 1E-03
Leukocyte transendothelial migration 1E-02
T cell receptor signaling pathway 2E-03
Toll-like receptor signaling pathway 2E-02 9E-02
Nervous System Neurotrophin signaling pathway 7E-06
Transport and Catabolism Endocytosis 3E-04
Human Diseases Cancers Acute myeloid leukemia 2E-02
Basal cell carcinoma 3E-05
Chronic myeloid leukemia 8E-03 9E-03
Colorectal cancer 1E-02 4E-02 3E-02
Endometrial cancer 6E-02 1E-02
Glioma 1E-01
Pancreatic cancer 3E-02
Pathways in cancer 3E-07 3E-03
Prostate cancer 4E-02
Renal cell carcinoma 3E-02
Small cell lung cancer 1E-02
Thyroid cancer 5E-03
Circulatory Diseases Arrhythmogenic right ventricular cardiomyopathy (ARVC) 6E-02
Hypertrophic cardiomyopathy (HCM) 2E-04
Infectious Diseases Epithelial cell signaling in Helicobacter pylori infection 2E-05
Neurodegenerative Diseases Amyotrophic lateral sclerosis (ALS) 6E-02
With genes in each module of the network, pathway enrichment analysis was performed using one-sided Fisher exact test. The significance level of p-value is represented by regular (0.01~0.1), bold (0.0001~0.01)
and bold-italic (<0.0001) fonts.
C
h
o
e
t
a
l
.
B
M
C
M
e
d
i
c
a
l
G
e
n
o
m
i
c
s
2
0
1
1
,
4
:
8
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
7
5
5
-
8
7
9
4
/
4
/
8
P
a
g
e
1
1
o
f
2
0Transcription factors and miRNA may co-regulate
biological networks
The most direct effects of miRNAs are through the spe-
cific interaction with their mRNA targets, affecting the
stability of these mRNAs or attenuating protein transla-
tion. The more complex and broad indirect effects of
miRNAs occur when they engage regulatory networks
by modulating the levels of specific TFs. These effects
are more numerous, pervasive, and difficult to untangle.
For example, the mRNA for NFYA is a predicted target
for miR-429, and the level of this mRNA may therefore
be affected by the level of miR-429 (Figure 4b). Since
NFYA regulates many other genes and miRNAs, a large
biological network may be affected by this specific
miRNA-TF connection. In addition, miRNAs may work
in conjunction with TFs to modulate the activity of var-
ious molecular processes. Examples of this type of more
complex regulatory circuit, feed-forward loops (FFL),
have been described and analyzed in E. coli and yeast
[38,39]. A FFL has at least two branches, with either
activation or suppression toward its targets. It is called a
coherent FFL when all the regulatory signals are syner-
gistic; otherwise, it is termed an incoherent FFL [40].
They can have specific regulatory characteristics, for
example a coherent FFL effectively filters out rapid fluc-
tuations in the inputs.
To identify FFLs composed of DEmiRNAs, DETFs,
and DEGs, we compiled all putative interactions among
them and applied statistical filters (FDR<0.1 for all
DETF-DEmiRNA and DETF-DEG interactions, see
Additional file 1). Among the entire 170 nodes (13
DETFs and 46 DEmiRNAs with 111 DEGs) that consti-
tuted the FFL network, JUN, NFYA, ZEB1, and miR-23a
emerged as the top 4 most “connected” nodes (Figure
5). For example, JUN, miR-195 and AXUD1 consist of a
coherent FFL since regulatory effects of JUN and miR-
195 would be expected to act together to decrease the
level of AXUD1 protein expression. On the other hand,
NFATC4, miR-29b and COL3A1 represent an incoher-
ent FFL since NFATC4 and miR-29b regulate COL3A1
in the opposite directions. Because of the potential for
significant regulatory impact of the EMT process, we
explored in more detail one of the predicted FFLs that
includes ZEB1 and the mir-23 miRNA cluster.
Identification of additional regulatory factors that
influence EMT
ZEB1 encodes a key transcription factor that acts down-
stream of TGF-b which has been implicated in EMT
[41]. We observed elevated levels of Zeb-1 mRNA
expression in our ILD samples (Figure 4A, B; Figure 5)
which led us to examine its role downstream of TGF-b in
more detail. Zeb-1 has 19 direct interacting DEmiRNAs,
based on predicted interactions. As with Zeb-1, the levels
of a number of these miRNAs, especially miR-23a, miR-
24, miR-26a, and miR-27a were elevated in the ILDs.
These miRNAs are encoded at a single genomic locus on
chromosome 19p13, the miR-23a cluster. Further, we
noted that there are two E-box motifs, or presumptive
binding sites for Zeb-1, in the distal promoter of the
miR-23 locus (Additional file 8). Thus, we explored the
possibility that Zeb-1 regulates or co-regulates the tran-
scription of miRNAs in the miR-23a cluster.
To test whether Zeb-1 can influence the induction of
the miR-23a cluster and to investigate what the conse-
quences might be, we used an in vitro EMT model in
the well-characterized Madin-Darby canine kidney
(MDCK) epithelial cell line. These cells normally express
high levels of E-cadherin, other epithelial cell markers,
and a low level of Zeb-1 and they exhibit the morphol-
ogy of an epithelial cell (Figure 6A) An increase in Zeb1
expression results in an EMT [41] leading to a mesench-
ymal morphology (Figure 6B). Separate MDCK cell lines
(derived by us from single-cell clones) were constructed
in which either Zeb-1 or the miR-23a cluster was over-
expressed. Over-expression of Zeb-1 caused a dramatic
increase in the levels of all the miRNAs that make up
the miR-23a cluster, while over-expression of these miR-
NAs had no such effect on Zeb-1 mRNA as shown in
Figure 6D. This is consistent with the miR-23a cluster
being positively regulated at the level of transcription by
Zeb-1. We next explored which possible targets of the
miR-23a cluster might be part of this signaling pathway.
Through computational target prediction, ‘neural pre-
cursor expressed, developmentally down-regulated pro-
tein 4-like’ (NEDD4L), which showed significantly
reduced expression in ILD (-2.46 fold) was identified as
one of the targets for the members of the miR-23a clus-
ter. Indeed, high levels of Nedd4L protein are readily
detected in MDCK cells that have an epithelial mor-
phology. There are several forms of Nedd4L protein
present, as reported in the literature. The predominant
form of Nedd4L detected in our Western blot is dis-
tinctly different between MDCK cell clones with epithe-
lial or mesenchymal morphology, or in epithelial MDCK
cells overexpressing Zeb-1 (Figure 6E). Nedd4L, a ubi-
quitin ligase, has been shown to down-regulate TGF-b
pathway activity, possibly by triggering Smad2/3 and
TGF-b type I receptor (Tgfbr1) ubiquitination and pro-
teasome-dependent degradation [42,43]. We are there-
fore currently testing the role of Nedd4L in ILD
processes. Lower levels of Nedd4L in ILDs may result in
higher TGF-b signaling activity in these tissues.
Together, these findings suggest that Zeb1-mediated
EMT, through mir-23a cluster regulation of Nedd4L
protein levels, may stabilize or enhance the activity of
TGF-b signaling and thus contribute to disease persis-
tence (Figure 6F).
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Page 12 of 20Integrated biological networks can be used to classify
pathology
A key reason to build integrated molecular network
models is to understand the pathological changes at a
molecular level between normal and ILD states. How-
ever, only some of the modules defined in Figure 4 var-
ied among different FVC groups or subtypes of ILDs.
Modules 4 and 5 showed changes between FVC group 1
and group 2; specifically the transcription factors in
these modules showed 2 to 8 fold increases from the
FVC group 2 to the FVC group 1 (Figure 7a). Genes
associated with signaling pathways are enriched in these
t w om o d u l e s( T a b l e3 ) .E x c e p tb e t w e e nF V Cg r o u p1
and FVC group 2 in modules 4 and 5, we could not
identify significant changes at the network level either
between the FVC group 2 and FVC group 3, or between
patient groups with different diagnoses.
However, when we grouped the patients based on the
expression levels of key molecules having roles in the
progression of disease, such as MYOCD or ZEB1 (see
Additional file 1), several significant correlations were
identified. In patient samples with high MYOCD expres-
sion levels, we observed significantly higher levels of
DEGs related to smooth muscle cytoskeleton, the extra-
cellular matrix and the EMT process (Figure 7b). This
observation correlates well with the hypothesis that a
higher level of MYOCD expression is linked to a higher
number of fibrocytes in the tissue. In the case of Zeb1,
there were significant changes in the levels of DEGs that
putatively interact with Zeb1 mRNA or protein (module
6 in Figure 4A). Interestingly, the levels of several Krup-
pel-like transcription factors (KLF) including KLF3,
KLF4, KLF6 and KLF9 in ILD patients paralleled
changes with the ZEB1 (higher levels of ZEB1 with
Figure 5 Examples of potential feed forward regulatory loops. A potential feed forward loop (FFL) was generated if a DEmiRNA and its
predicted regulatory transcriptional factor targeted the same DEG (see Additional file 1). Red, blue and gray lines represent the predicted
transcriptional activation (i.e. positive correlation), predicted transcriptional repression (i.e. negative correlation) and relationships between
DEmiRNAs and their predicted targets (without considering expression correlations), respectively. The left inserts illustrate coherent and
incoherent FFLs. JUN, miR-195 and AXUD1 form a coherent FFL in which transcriptional (from JUN to AXUD1) and miRNA-mediated regulation
(from JUN to AXUD1 via miR-195) are synergistic. In contrast, NFATC4, miR-29b and COL3A1 form an incoherent FFL in which two opposite
regulatory interactions occur.
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Page 13 of 20lesser decreases in the KLFs). The fact that changes in
some modules are apparently associated with different
levels of key genes involved in the ILDs suggests that it
may be valuable to use molecular profiling and network
modeling in order to group and stratify patients which
could aid in better understanding and treating ILDs.
Discussion
While the earliest inciting events that result in ILDs
remain unclear, IPF and some closely related interstitial
lung diseases share a clinical course in which a zone of
fibrosis expands at the expense of alveolar structures
[1,4]. The relentless expansion of fibrosis and the failure
of re-epithelialization suggest that the initiation, mainte-
nance, and resolution of the tissue repair process in ILD
lungs are probably changed in some fundamental ways.
To understand these processes in more detail, we inves-
tigated expression of mRNA and miRNA in human lung
b i o p s ys p e c i m e n sf r o mp a t i e n t sw i t hI L D sa n d
compared the findings with control lung samples to
identify the networks and regulatory modules involved
in disease.
Global transcriptome analysis, including miRNAs, is a
useful tool to investigate how molecular networks
change between biological states. However, caution is
called for when interpreting these data. RNA profiling
methods measure the concentrations of RNA (for both
m R N Aa n dm i R N A )a tas p e c i f i cs t a t e ;d y n a m i c a l l y
modulated processes and transcripts can be missed. In
addition, this approach cannot detect regulatory changes
associated with translation of messages. Nor do the
levels of miRNAs always correspond to their regulatory
activities, which can be modulated by other proteins or
RNAs. Significant variations in measurements can also
come from sample heterogeneity and sample prepara-
tion, such as the difference in biopsy locations, the het-
erogeneity of the disease within the biopsy sample, the
diverse spectrum of cell types in the sample, and genetic
Figure 6 The Zeb-1 mediated EMT is partially regulated by miRNAs in the miR-23a cluster. (A-C) Phase contrast images showing the
morphology of an epithelial MDCK clone (A; 3E11), the same epithelial clone stably over-expressing Zeb-1 (B; 3E11+Zeb1), or a mesenchymal
MDCK clone (C; 2F7). (D) Over-expression of Zeb-1 causes the levels of miR-23a, miR-24 and miR-27a to rise dramatically, while over-expression
of the miR-23a cluster of genes had no effect on the level of Zeb-1 mRNA, relative to mock-transfected cells. (E) Nedd4L Western: MDCK clone
3E11 has an epithelial morphology and expresses 4 bands that are recognized by an anti-Nedd4l antibody (green). One of these bands (marked
with asterisk) was dramatically reduced in MDCK cells with mesenchymal morphology (clone 2F7) or in an epithelial MDCK cell line stably over-
expressing Zeb-1 (3E11+Zeb1). The significance of each of the four bands recognized by the anti-Nedd4L antibody remains unclear. However, a
similar pattern of bands was observed using a second anti-Nedd4L antibody (data not shown). Anti-Argonaute 2 (Ago2; red) antibody was used
as loading control. (F) A hypothetical model for the role of the Zeb-1, the miR-23a cluster, and Nedd4L in TGF-b mediated EMT. The genes and
miRNAs involved in the process are listed and the colors indicate the relative expression changes in ILD samples compared to control, red
indicates higher level in ILDs, yellow indicates no significant changes, while green represents lower levels in ILD samples compared to control.
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Page 14 of 20and environmental effects on individuals. Finally, the
profiling methods used in the study can only observe
the average effect of multiple cell types and numbers of
cells in different states in the sample which can add
uncertainly to the data. The generally modest correla-
tion among different miRNA measurement platforms
[44] also needs to be taken into consideration when
comparing data from other studies. Nonetheless, with all
these qualifications, global mRNA/miRNA profiling is
currently the most powerful available approach to iden-
tify disease associated molecular networks.
By analyzing mRNA and miRNA spectra, we identified
1423 differentially expressed genes and 125 differentially
expressed miRNAs between ILD and control lung sam-
ples. Comparing the data from three male and three
female control lung samples, females generally exhibit
lower (albeit modestly) levels of expression of both
mRNA and miRNA than males. There are exceptions,
however, for example, the average levels of miR-101 and
miR-27b are 8 times higher (per cell) in males than in
females, and Atlastin3 (ATL3) and Sec23 homolog A
(SEC23A) mRNA are three times higher in males when
compared to females. Unfortunately, we do not have
sufficient numbers of samples to determine whether
these gender differences play any role in the progression
of ILDs. Interestingly, gender-associated pathological
development has been observed in other lung conditions
[45,46]. It is certainly worth further investigation in the
future with larger, carefully age- and gender-matched
sample sets.
Regardless of gender, our data also indicates a general
inverse trend in global gene expression patterns as the
severity of the disease increases and as lung function
decreases (Figure 1). For example, mRNAs for the tran-
scription factors, MYC and JUNB show significant dif-
ferences in samples from patients in FVC group 3 (lung
function greater than 80% of normal) and group 2 (lung
function between 50 to 80% of normal), but almost no
change in samples from FVC group 1 patients (lung
function less than 50% of normal) when compared to
controls. This contradicts the general expectation of lar-
ger changes in more advanced disease. However, in
ILDs there is significant tissue remodeling and func-
tional adaption. Individuals with the most severe dis-
ease, FVC group 1, may adapt to the deficiency of lung
capacity, and the repopulation of the lung parenchyma
with fibroblasts may also mask the signals from stressed
pulmonary epithelial cells, which are proportionally a
smaller and smaller fraction of the tissue as disease
progresses.
Figure 7 Examples of sub-networks associated with different patient classifications. Examples of sub-networks that show significant
changes in some key genes associated with FVC groups 1 and 2 (A), MYOCD (B), or ZEB 1 (C) expression levels. The corresponding FVC group
and MYOCD or ZEB 1 genes are labeled in the sub-networks. The levels of expression are indicated as in the previous figures.
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Page 15 of 20Pairs of genes and miRNAs can be used to distinguish
different disease types
Biomarkers that help diagnose the ILDs or that can dis-
tinguish idiopathic pulmonary fibrosis from other forms
of ILDs, or reflect the severity of a disease would be
useful tools to combine with other clinical information
such as patient histories, pulmonary function tests, and
radiographic findings to achieve better diagnosis of the
diseases. Using “top scoring pair analysis”, we identified
several pairs of mRNAs and microRNAs that had the
power to discriminate ILDs from controls (see Addi-
tional files 4 and 5). The most robust pairs, COL3A1
and ARHGEF7, and miR-99b and miR-21*, can perfectly
discriminate the ILD samples from controls (Additional
file 5) in our sample set. Using the same approach, we
also identified mRNA pairs that distinguish IPF from
NSIP (Additional file 5). Even though these mRNA or
miRNA pairs can successfully distinguish ILDs from
normal or separate UIP/IPF from NSIP, these candidate
markers were derived from lung tissue biopsies, which
are not routinely used in the clinic; as a result, their
immediate value may be limited.
Several pathways are significantly perturbed in disease
As in previous studies, our transcriptomic study also
revealed a number of strongly perturbed pathways in
the ILDs. These include TGF-b, Wnt signaling, focal
adhesion, extracellular matrix-receptor interactions,
insulin signaling, MAPK signaling, B-cell signaling,
adipocytokine signaling, and vascular smooth muscle
contraction pathways [4,7,9]. The involvement of
these pathways clearly suggests the involvement of
the immune response and a disruption of the normal
cellular microenvironment in the ILDs. We also
observed that a number of metabolic processes such
as glycine, serine and threonine metabolism and ster-
oid biosynthesis were suppressed in the ILD samples,
which implies a decrease in general lung metabolic
activities in ILD patients. Consistent with this finding
from DEGs, we also observed changes in several
immune response related miRNAs including miR-100,
mir-21, miR-140, miR-146, miR-155, and miR-223
[47,48].
An interesting finding of the pathway enrichment ana-
lyses is the similarity of the differentially expressed mRNA
we observed with the predicted target mRNAs of the dif-
ferentially expressed miRNAs (Table 2). This suggests that
the miRNAs we observed may have key roles in regulating
the basic pathological processes of the ILDs as illustrated
by pathways for Wnt signaling, ECM-receptor interaction,
focal adhesion, vascular smooth muscle contraction, adi-
pocytokine signaling and insulin signaling.
Focusing on transcription factors and miRNAs provides
an incisive view of regulatory networks associated with
ILDs
Even though pathway enrichment analysis with DEGs
and DEmiRNA targets allowed us to identify molecular
pathways associated with ILDs, this approach has two
limitations: 1) it limits us to previously curated pathway
information and 2) it lacks sufficient information to
build an integrated view associated with ILDs from the
dataset. We thus focused on the transcription factors
and miRNAs, to provide a global view of the regulatory
machinery involved in the ILDs. We computed a net-
work with 640 DEGs, and 49 miRNAs with a total of
1391 interactions (excluding DEmiRNA-DEG interac-
tions). Compared to a simple pathway-based analysis, in
which only 395 of the 1423 identified DEGs could be
assigned to any pathway, this transcription factor and
miRNA-mediated network analysis allowed us to cap-
ture and integrate much more information. It is impor-
tant to realize however, that until we can measure the
cognate protein levels for all the relevant genes in these
networks, the translation regulation component of the
network will remain hidden. This component undoubt-
edly plays an important role in the disease-related net-
work regulation, and so it must be a priority for future
work to assess the protein levels for all the relevant
genes if we are to understand the perturbation of these
gene networks more completely.
G r o u p i n gt h em o s th i g h l yi nteracting nodes together
[49], the network can be grouped into 7 modules. It is
encouraging that the biology is reflected in this group-
ing, since the modules align with functional associations
based on pathway and GO term enrichment analyses
(Table 3 and Additional file 1). For example, module 1
contains genes from a number of metabolic pathways,
and module 2 contains genes involved in immune
responses and signal transduction processes (Table 3).
This approach also allows us to integrate various mole-
cular processes into a single module and reveal key
molecules linking these processes. For example, CDC42,
phospholipase C, beta 4 (PLCB4), mitogen-activated
protein kinase 14 (MAPK14), and Src homology 2
domain containing transforming protein 3 (SHC3)a r e
all located in module 2 and these gene products are
clearly involved in the receiving and transmission of var-
ious extracellular signals to the nucleus.
Because of their documented functions, genes like
MYOCD or ZEB1 may be used as indicators of EMT or
the presence of mesenchymal cells such as myofibro-
blasts in the ILD samples. Indeed, when we grouped
patients based on the expression levels of these genes,
several groups of genes related to MYOCD or ZEB1
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Page 16 of 20were revealed. In addition to the obvious sub-networks
representing changes in the cytoskeleton, the extracellu-
lar matrix and the process of EMT (Figure 7), several
key transcription factors such as the zinc-finger KLF
family members, JUN, MYC, EGR1,a n dMEIS1 also
showed significant changes associated with the MYOCD
and ZEB1 mRNA expression levels. The involvement of
these transcription factors and their effects on the ILDs
warrants further study with more patient samples and
different clinical pathologies.
Another reason to build an integrated molecular net-
work associated with ILD is to gain a better understand-
ing of the overall pathology. In most cases we could not
observe a clear association between the changes of net-
work modules with different clinical conditions such as
FVC groups or diagnosed subtypes of ILDs. This most
likely reflects diversity in the ILD pathologies, the differ-
ing degrees of progression and especially the difficulty
of making precise and consistent clinical observations
embodied in the recorded diagnoses. This further illus-
trates the need for new approaches like those used here,
such as using the levels of ZEB1 and MYOCD mRNAs
to provide a more consistent and accurate clinical strati-
fication in this complex of diseases.
Anti-apoptosis signal may promote survival of
myofibroblats in ILD lungs
The lung tissues from ILDs in general, and from IPF in
particular, are enriched with myofibroblasts. Myofibro-
blasts utilize their actin-linked cytoskeletal machinery to
migrate, proliferate, form foci and perhaps contract
under stimulation. A series of up-regulated genes, from
calcium and potassium regulated channels located at the
cell membrane (calcium channel, voltage-dependent, L
type, alpha 1C subunit (CACNA1C) and potassium large
conductance calcium-activated channel, subfamily M,
beta member 1 a (KCNMB1)), to the cytosolic genes
that regulate the levels of secondary messengers
(cyclicGMP, cyclicAMP, diacylglycerol, Ca
++, inositoltri-
phosphate) to myosin light chain kinases, (MYLK and
MYLK3) actins, and myosins (MYL9, MYH11, ACTA2,
ACTG2), outline key molecular pathways and constitute
an unmistakable signature of the myofibroblast. These
genes are clustered on the lower right corner of module
1 (Figure 4a). The apparent monolithic expression
changes of genes associated with a-smooth muscle net-
works are in agreement with the abundance of myofi-
broblasts in the biopsy tissue we studied. The strong
down-regulation of several apoptosis related genes such
as receptor-interacting serine-threonine kinase 1(RIP1),
bcl2-associated X protein (BAX), and phosphoinositide-
3-kinase (PI3K) may also contribute to the resistance to
apoptosis of the myofibroblasts.
miRNAs from the miR-23 cluster may mediate Zeb1
induced epithelial to mesenchymal transition through
modulating TGF-b activity
The origin of the fibroblasts in the ILD lung could come
from three major sources–the proliferation of resident
pulmonary fibroblasts, the recruitment of circulating
fibrocytes into the lung and EMT of pulmonary epithe-
lial cells. Zeb-1 has been shown to be a positive regula-
tor of mesenchymal cell related genes; it can participate
both in epithelial to mesenchymal as well as a mesench-
ymal to epithelial transitions [50]. Prolonged exposure
to TGF-b has been seen to induce expression of the
transcription factors Zeb-1 and Zeb-2, leading to EMT.
In addition to other targets, Zeb-1 and Zeb-2 are known
to negatively regulate expression of the miR-200 family.
These miRNAs have been proposed to maintain an
epithelial phenotype in some cells and their decline in
response to Zeb-1 commits the cells to transition to a
mesenchymal phenotype [51-54]. In our ILD samples,
we observed a significant increase of Zeb-1 mRNA levels
which is consistent with a role in EMT in the ILD. Sur-
prisingly, we also observed an increase in the miR-200
family in our ILD samples. These observations raise the
possibility that both processes could be active in our
lung tissue biopsies, but in different cells: negative regu-
lation of EMT mediated by miR-200 family in epithelial
cells and positive regulation of EMT, mediated by TGF-
b, Zeb-1, and the miR-23 cluster, in transitional cells
and mature fibroblasts.
Our network analysis also suggested a preliminary
model for how a signal from TGF-b could result in
transcriptional and post-translational regulation that
would lead to EMT and maintenance of the mesenchy-
mal myfibroblast compartment in ILD. Zeb-1 mRNA
expression was up-regulated in ILD as was the expres-
sion of miR-23a, miR-27a and miR-24. These miRNAs
are encoded at one locus in the human genome at
19p13 and constitute the miR-23a cluster. The similar
expression profile of these miRNAs in our ILD data sug-
gested that Zeb-1 may positively regulate this cluster of
miRNAs. Putative binding sites for Zeb-1 proximal to
the cluster support this hypothesis (see Additional file
8). We investigated this relationship further by over-
expressing Zeb-1 in MDCK cells in vitro,w h i c hc o n -
firmed this suggestion: Zeb-1 clearly caused the levels of
the miR-23a cluster to increase (Figure 6D). In addition,
we identified the ubiquitin ligase Nedd4L as likely being
subject to post-transcriptional negative regulation by the
miR-23a cluster, which is driven in turn by over-expres-
sion by Zeb-1. The changes in Nedd4L expression are
shown in Figure 6E. We believe the presence of multiple
Nedd4L isoforms in the Western blot is due to the com-
bined effect of alternative start codons and alternative
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will be reported elsewhere). It is also possible that these
results, based on the use of a kidney cell line, may not
be applicable in all details to the lung. Since Nedd4L
accelerates the degradation of Smad2/3 and Tgfr1,
thereby attenuating TGF-b signaling [42,43], the Zeb-1
feed forward loop (FFL) we identified here is likely to be
a component of the larger pathway by which TGF-b sig-
naling contributes to EMT, and thus to expansion and
persistence of the myofibroblast compartment in ILD. In
susceptible pulmonary epithelial cells, TGF-b signals via
Smad2/3 and 4 to upregulate Zeb-1, which in turn pro-
motes the transcription of the miR-23a cluster of miR-
NAs. These miRNAs suppress Nedd4L activity at a
post-transcriptional level, resulting in uninterrupted sig-
naling activity from Smad2/3 (Figure 6F). We believe it
should be possible to validate this aspect of TGF-b sig-
naling in myofibroblasts derived from ILD tissue. It
illustrates the utility of network predictions based on
comprehensive transcriptome data, and suggests a pro-
mising line of further investigation.
Recently, Pandit et al. [55] reported that the level of
let-7d, regulated by TGF-b signaling, may play a role in
EMT and contribute to IPF pathogenesis. This conclu-
sion was partly based on the observed increase of
mesenchymal markers including CDH2, VIM and
ACTA2 relative to let-7d levels. We also have observed
perturbation of the TGF-b p a t h w a y( T a b l e3 ,F i g u r e4 a .
module 5 and 6), over-expression of ZEB1 (Figure 4A,
module 6), and increased levels of mesenchyme-asso-
ciated genes such as ACTA2, CDH2 and VIM in ILD
patients (Figure 4A, module 1). Although Pandit et al.
and our study agree on the observation of mesenchymal
markers and the lack of a significant decrease in the
miR-200 family, we did not observe a decrease in let-7d
in the ILD patient samples in this study. This difference
could be due to the fact that our patient population has
am o r ed i v e r s es e to fd i a g n o s e s ,e v e nt h o u g hn o n eo f
the IPF patients in our study were observed to exhibit
this decrease, or to different miRNA quantitation meth-
ods. These overall findings support the idea of multiple
parallel processes involved in perturbing key biological
pathways or networks in the pathogenesis of ILD.
Conclusions
Systems biology approaches yield a much more com-
plete picture of how signaling networks and groups of
co-expressed genes are involved in ILDs, which may
help to explain key aspects of disease pathogenesis. The
transcription factor and miRNA-based network analysis
allows us to gain a global view of the molecular control
networks associated with ILDs. It also provides new
insights into the diseases and generates new testable
hypotheses, such as how Zeb-1 activity is partially
mediated through the miRNAs in the miR-23a cluster
(Figure 6F). Our network and pathway analyses helped
clarify two processes that are fundamental to ILD patho-
genesis: the strong anti-apoptosis signal and the origin
of myofibroblasts via EMT. Taken together, these pro-
cesses help explain why the progressive pro-fibroblast
environment fails to resolve. We validated the possible
involvement of the miR-23a cluster in modulating TGF-
b activity to facilitate the Zeb1-mediated EMT process.
This finding may provide new therapeutic targets for
intervention, such as anti-miR therapeutics delivered to
the lung to decrease Zeb-1 activity. Another interesting
possibility is specifically to induce apoptosis of
fibroblasts.
We have demonstrated here the power of focusing on
the key regulatory components, the transcription factors
and miRNAs, in order to gain insight into the networks
perturbed in complex diseases such as ILDs. The
inferred network: 1. provides a global view of the effects
of DETFs and DEmiRNAs, 2. is not limited to individual
molecular processes or pathways, and 3. uses informa-
tion beyond curated databases to link molecules and
networks. Despite the apparent conceptual simplicity of
this approach, it is difficult to construct such networks,
and most of the miRNA and TF mediated interactions
are not yet well-characterized. In addition, there is no
definitive method by which to modularize the network
so that functional implications can be easily viewed and
extracted. Our approach therefore needs further devel-
opment in data integration and visualization; neverthe-
less, it represents a significant step in the global view of
perturbed network in the complex of interstitial lung
diseases. Lacking longitudinal time-course samples or
samples accurately matched to disease state progression
prohibits following the dynamic changes in ILD. Tem-
poral dynamics is one of the most powerful elements
needed to fully unravel the biology of a system. Integrat-
ing data from properly chosen model systems should
allow us to gain a better understanding of disease initia-
tion and progression. We would expect that some of the
same networks are perturbed in these models, and allow
us to build better network-based molecular models to
identify, test and predict new therapeutic interventions.
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